

IN THE PATENT AND TRADEMARK OFFICE

In Re Application of:	Art Unit: 4131
Karl OKOLOTOWICZ	Examiner: Rider, Lance W.
Serial No.: 10/516,352	Confirmation No.: 9543
Filed: July 20, 2005	
For: TOLUIDINE BLUE O DRUG SUBSTANCE AND USE THEREOF FOR IN VITRO STAINING AND CHEMOTHERAPEUTIC TREATMENT OF DYSPLASTIC TISSUES	

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Dear Sir/Madam:

In accordance with applicant's duty to disclose information that may be material to the examination of this application, 37 CFR § 1.56, attached hereto is an Information Disclosure Statement.

The submission of any document herewith is not intended as an admission that such document constitutes prior art against the claims of the present application. Applicant does not waive any rights to take any action that would be appropriate to antedate or otherwise


remove as a competent reference any document that is determined to be a prima facie prior art reference against the claims of the present application.

Applicant respectfully requests that the attached Information Disclosure Statement and references be considered by the Examiner and be made of record in the present application and that a copy of the initialed, signed, and dated e-IDS form be returned in accordance with MPEP Sec. 609.07.

It is believed that no additional fee is due for submitting this document. However, in the event a fee is required, the Commissioner is authorized to charge any amounts due or credit any overpayments in connection with this matter to Deposit Account No. 10-0440.

Respectfully submitted,

Date: April 4/22, 2009



Brennan C. Swain, Esq.
Registration No. 43,175
Jeffer, Mangels, Butler & Marmaro LLP
1900 Avenue of the Stars, 7th Floor
Los Angeles, CA 90067
310-203-8080
Customer No. 24574